

BIOHAZARDOUS AGENT REFERENCE DOCUMENT

Lymphocytic choriomeninigitis virus (LCMV)

The Biohazardous Agent Reference Document (BARD) is a general guidance resource that reviews and summarizes the nature of a pathogen or biotoxin, and offers safety requirements for work with the agent in the laboratory. The BARD may replace the formal SOPs used in conjunction with some IBC registrations.

The BARD is provided as an additional guidance tool, and is not a substitute for a risk assessment, biosafety training, lab-specific training, or a formal <u>IBC master protocol registration</u>. This document should be readily available in the laboratory, and it is the responsibility of the Laboratory Supervisor or Principal Investigator to ensure that all personnel have read, understood, and signed the document. The BARD is for informational purposes only, and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please consult a health care provider for any medical questions or concerns.

INSTRUCTIONS

- 1. Review the information contained in this document.
- 2. Add any necessary information that is specific to your work in the laboratory (such as strain-specific information). Please be sure that the track changes function is turned on to indicate any changes that you make.
- 3. Instruct all personnel to review the BARD and sign the last page, indicating that they have read and understood the information.
- 4. Submit the BARD along with your IBC master protocol registration, amendment, or continuing review.



BIOHAZARDOUS AGENT REFERENCE DOCUMENT

Lymphocytic choriomeninigitis virus (LCMV)

CHARACTERISTI	CS
Morphology	Member of the Arenaviridae family, enveloped
	virus.
Strain Specific	Armstrong strain: in mice, increases viral titers
Characteristics	for 3-4 days then declines to clear completely.
	Clone 13 strain: increases viral titers for months
	after infection and causes immunosuppression.
	It is thought that the clone 13 strain is more
	virulent and has caused lab-acquired infections.
	We strain: has been found to be lethal in non-
	human primates (NHPs).

HEALTH HAZARDS	
Host Range	House mice are natural hosts. LCMV can also
	infect humans and other animals (hamsters,
	guinea pigs, NHPs)
Modes of	LCMV is excreted through mouse urine, saliva,
Transmission	and feces, Transmission occurs through
	inhalation, ingestion, contact with mucous
	membranes, and breaks in the skin. Vertical
	transmission is possible from mother to child.
	There is no other evidence of human to human
	transmission.
Signs and	First Phase: febrile illness (fever, lack of
Symptoms	appetite, muscle aches, nausea, vomiting,
	headache, and malaise).
	Second Phase: meningeal symptoms,
	encephalitic symptoms, and myelitis (swelling of
	the spinal cord).
Infectious	Unknown
Dose	
Incubation	8 – 13 days
Period	

MEDICAL PRECAUTIONS / TREATMENT	
Prophylaxis	None available
Vaccines	None available
Treatment	None available
Surveillance	Monitor for symptoms and test using serology
	and viral isolation
UVM IBC	Report any exposures or signs and symptoms to
Requirements	your supervisor
Additional	Women who are pregnant or planning on
Medical	becoming pregnant should be aware that
Precautions	pregnant women infected with LCMV can
	transmit the virus to their fetus. This can result
	in loss of pregnancy or serious birth defects.

LABORATOR	/ HAZARDS
Laboratory	There have been well documented LAI's from
Acquired	infected animals and contaminated cell lines. 46
Infections	cases with 5 deaths have been documented.
Sources	Urine, saliva, blood, tissues, cerebrospinal fluid,
	nasopharynx secretions, and feces from infected
	humans, animals and contaminated cell lines.
CONTAINME	NT REQUIREMENTS
BSL - 2	Manipulation of known or potentially infected
	clinical samples and cell cultures of laboratory
	adapted strains (RG2)
BSL - 3	Manipulations involving high aerosol potential, high
	concentrations or volumes of virus, and strains
	lethal to NHP's (RG3).
ABSL - 2	Work with animals infected with risk group 2 strains
ABSL - 3	Work with animals infected with RG3 strains.
Aerosol	Centrifugation, homogenizing, vortexing or stirring,
generating	changing of animal cages, animal surgeries, cell
activities	sorting, pipetting, pouring liquids, sonicating,
	loading syringes
Primary	Use for aerosol-generating activities, high
containment	concentrations, or large volumes
device (BSC)	

EXPOSURE I	PROCEDL	IRES
Mucous	Flush eyes, mouth or nose for 15 minutes at	
membran	eyewash station.	
es		
Other	Wash a	rea with soap and water for 15 minutes
exposures		
Medical	Contact	UVMMC Infectious Disease Dept. directly
Follow-Up	at (802)	847-2700 for immediate assistance
Reporting	Report	all exposures or near misses to:
	1.	Your immediate Supervisor
	2.	The UVM Biosafety Officer at (802) 777-
		9471 and Risk Management at 6-3242
	3.	Risk Management and Safety;
		https://www.uvm.edu/riskmanagement/i
		ncident-claim-reporting-procedures

PERSONAL PROTECTIVE EQUIPMENT (PPE)	
Minimum PPE	Nitrile gloves, lab coat, appropriate eye/face
Requirements	protection. Wash hands after removing gloves.
Additional	Sharps use strictly limited. Due to modes of
Precautions	transmission, respirators may be required when
(Risk	working with LCMV. Medical clearance, fit testing
assessment	and training is required annually per UVM's
dependent)	Respiratory Protection Program;
	https://www.uvm.edu/riskmanagement/personal-
	protective-equipment



BIOHAZARDOUS AGENT REFERENCE DOCUMENT

Lymphocytic choriomeninigitis virus (LCMV)

VIABILITY	
Disinfection	Susceptible to 1% sodium hypochlorite, 2% glutaraldehyde, 70% ethanol, and formaldehyde;
	with 15-minute contact time
Inactivation	Inactivated by heat above 55°C for 20+ minutes
Survival	Capable of surviving outside of host in mouse
Outside Host	droppings

SPILL CLEAN	UP PROCEDURES
Small Spill	Notify others working in the lab. Allow aerosols to settle. Don appropriate PPE. Cover area of the spill with paper towels and apply approved disinfectant, working from the perimeter towards the center. Allow 30 minutes of contact time before clean up and disposal. Dispose in double biowaste bags and biobox.
Large Spill	Inside of a lab: Call UVM Service Operations at 656-2560 and press option 1 to speak to a dispatcher. Ask them to page Risk Management and Safety. Outside of a lab: Pull the nearest fire alarm and evacuate the building. Wait out front of the building for emergency responders to arrive.

REFERENCES	
Canadian PSDS	http://www.phac-aspc.gc.ca/lab-bio/res/psds-
	ftss/lymp-cho-eng.php
BMBL	https://www.cdc.gov/biosafety/publications/b
	<u>mbl5/</u>
CDC LCMV	https://www.cdc.gov/vhf/lcm/index.html
Guidelines	
Current	Welsh, RM et Al. (2008). Lymphocytic
Protocols in	Choriomeningitis Virus (LCMV): Propagation,
Microbiology	Quantitation, and Storage.
	https://www.ncbi.nlm.nih.gov/pubmed/187705
	<u>34</u>

STUDENT / EMPLOYEE NAME

SIGNATURE

DATE

Biosafety Review:

Jeff LaBossiere, Biological Safety Officer

Date

Principal Investigator: _____

IBC Registration #: _____